anti-SARS-CoV-1 spike protein mAb (Adagio Therapeutics)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-SARS-CoV-1 spike protein mAb (Adagio Therapeutics)
Drug Alias Nameanti-SARS-CoV-1 monoclonal antibody (Adimab)anti-SARS-CoV-1 monoclonal antibody (Adagio Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsSevere Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAdimab LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInvivyd IncAdimab LLC
Active IndicationsN/A
Inactive IndicationsSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A
Related LinksN/A